Summary:
- A randomized clinical trial investigated whether a 15-day course of Paxlovid (nirmatrelvir-ritonavir) would alleviate symptoms in patients with Long COVID compared to a placebo.
- The study concluded that the extended treatment duration provided no significant clinical benefit in reducing the severity or persistence of Long COVID symptoms, suggesting that viral persistence may not be the primary driver of the condition in this cohort or that the dosage/timing was insufficient.